An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections
Vaccines · 17.01.2023 · 11 (2) · 206
DOI: 10.3390/vaccines11020206 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 17.01.2023. Verfasst von Divya Sharma und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, Sector-III, Pushp Vihar, Government of NCT of Delhi, New De…. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 278 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Herpes simplex virus (HSV) infection, the most prevalent viral infection that typically lasts for a lifetime, is associated with frequent outbreaks of oral and genital lesions. Oral herpes infection is mainly associated with HSV-1 through oral contact, while genital herpes originates due to HSV-2 and is categorized under sexually transmitted diseases. Immunocompromised patients and children are more prone to HSV infection. Over the years, various attempts have been made to find potential targets for the prevention of HSV infection. Despite the global distress caused by HSV infections, there are no licensed prophylactic and therapeutic vaccines available on the market against HSV. Nevertheless, there are numerous promising candidates in the pre-clinical and clinical stages of study. The present review gives an overview of two herpes viruses, their history, and life cycle, and different treatments adopted presently against HSV infections and their associated limitations. Majorly, the review covers the recent investigations being carried out globally regarding various vaccine strategies against oral and genital herpes virus infections, together with the recent and advanced nanotechnological approaches for vaccine development. Consequently, it gives an insight to researchers as well as people from the health sector about the challenges and upcoming solutions associated with treatment and vaccine development against HSV infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, Sector-III, Pushp Vihar, Government of NCT of Delhi, New Delhi 110017, India.
- Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur 440033, India.
- Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University, Sector-III, Pushp Vihar, Government of NCT of Delhi, New Delhi 110017, India.
ORCID-Profile: Divya Sharma, Mahaveer Dhobi
Zitieren
APA
Sharma, D., Sharma, S., Akojwar, N., Dondulkar, A., Yenorkar, N., Pandita, D., Prasad, S. K., & Dhobi, M. (2023). An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections. Vaccines, 11(2), 206. https://doi.org/10.3390/vaccines11020206
Vancouver
Sharma D, Sharma S, Akojwar N, Dondulkar A, Yenorkar N, Pandita D, et al. An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections. Vaccines. 2023;11(2):206. doi:10.3390/vaccines11020206
BibTeX
@article{Sharma2023,
author = {Sharma, Divya and Sharma, Supriya and Akojwar, Natasha and Dondulkar, Ayusha and Yenorkar, Nikhil and Pandita, Deepti and Prasad, Satyendra K and Dhobi, Mahaveer},
title = {An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {2},
pages = {206},
doi = {10.3390/vaccines11020206}
}
EUVIMED